The collaboration will include joint development initiatives on predictive analytics and AI-based algorithms for improving cardiac care.

Cleveland Clinic’s existing critical care and non-critical care central monitoring platform provides continuous monitoring of a range of vital signs, including ECG, for both ICU and non-ICU patients at more than a 2,000-bed capacity. Its hospital-based RPM programs serve 11 hospitals, providing intensivist monitoring, 24/7 critical care nursing, and patient management. Cleveland Clinic’s programs¹ have reduced patient mortality and reduced ICU length of stay while increasing caregiver satisfaction.² With this partnership, Masimo and Cleveland Clinic hope to bring these innovations and patient benefits to other healthcare systems in the future. The aim of the enhanced program is to increase awareness and facilitate triage with proactive responses to changes in a patient’s condition. This improves patient care and saves lives by ensuring the highest risk patients are identified and receive timely treatment while maintaining quality of care for all patients.^1,2

The Masimo Hospital Automation platform offers technologies designed to help clinicians improve patient care at the bedside, across the care continuum. Masimo Hospital Automation includes monitoring and wearable technologies, high-fidelity medical device integration, system-wide applications for surveillance and data visualization, and novel AI capabilities that support intelligent patient prioritization and help clinicians identify changes in patients’ condition more efficiently.

These decision-support tools are integrated into the Masimo Hospital Automation platform and utilize the Halo engine, technology which identifies deterioration patterns in multiple physiological parameters simultaneously, in real time. The Halo tools include Halo ION^®, a comprehensive, scalable, and customizable continuous early warning score to help streamline patient assessment and clinical workflows. As part of their work together, Masimo and Cleveland Clinic are partnering to jointly develop an additional Halo-based decision-support tool to support clinicians with earlier detection of adverse events – ultimately helping them manage and improve patient outcomes more effectively, for low-, mid-, and high-acuity patients.

“We see great opportunities to enhance remote care, particularly for critically ill individuals,” said Chiedozie Udeh, M.D., Medical Director of ICU Operations at Cleveland Clinic. “By combining our technical and clinical expertise, we aim to improve situational awareness for clinicians and continue to improve outcomes for patients.”

Thomas Callahan, M.D., Staff Cardiologist at Cleveland Clinic’s Heart, Vascular & Thoracic Institute, and principal investigator for the AI study, added, “We look forward to exploring the effects of next-gen inpatient wearables, and as the capabilities of AI continue to advance, studying the potential impact on the care of cardiac patients, including those undergoing cardiac surgery.”

Joe Kiani, Founder and CEO of Masimo, said, “We are truly honored to have the opportunity to partner with Cleveland Clinic to advance patient care. By harnessing Masimo’s AI-powered decision support tools, automation solutions, and monitoring devices, alongside Cleveland Clinic’s vast clinical expertise and dedication to providing the highest quality, most innovative care, our partnership has the potential to significantly ease staff shortages, better standardize care, and promote intensivist- and specialist-led care. Ultimately, we will make significant strides in shifting from reactive to predictive and proactive care – improving patient outcomes, safety, and quality of care across the board.”

Dr. Chiedozie Udeh has a conflict of interest with Cleveland Clinic’s eHospital platform and may benefit from commercialization of eHospital technology developed by the Company. These financial interests are being managed by Cleveland Clinic and are within permissible limits established by the Institutional Conflicts of Interest Policy. eHospital is not a Masimo product.

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post Masimo & Cleveland Clinic Collaborate to Improve Hospital Remote Care first appeared on AI-Tech Park.

By leveraging AI and machine learning, Pill Count makes counting pills easier and more accurate. This is the latest solution for Outcomes, a company that offers a full suite of patient engagement, clinical and pharmacy workflow solutions across the nation’s largest community network of retail, chain and grocery pharmacies.

“Efficiency and error prevention are critical success factors in pharmacy management,” says Chief Commercial Officer Angela Host. “We have now made the concept of scan, count, capture and fill extremely easy. The pharmacy saves time, which enables more revenue generating activities, and by leveraging computer vision and machine learning, Pill Count reduces medication errors by more than 8% and provides real-time prescription count with 99.92% accuracy.”

In addition to Pill Count, Outcomes will highlight its full suite of offerings at booth #812, including:

Rx30^® integration with Outcomes

This integration provides pharmacists with a bi-directional single sign on (SSO) that streamlines the login process and enables Rx30 dashboard features to be displayed directly within Outcomes. The ability to identify which patients have an open Outcomes clinical opportunity within Rx30 is a major step forward in providing pharmacists with a fully integrated platform.

OutcomesIndex

The company’s latest analytical offering brings together clinical activity and dispensing behavior to highlight the most successful pharmacy characteristics. OutcomesIndex provides timely access to a breadth of important trends in the United States pharmacy market.

Outcomes will also be demonstrating how their products can help pharmacies optimize revenue at an evening reception from 5-7 p.m. on June 24 at the New Orleans Convention Center, Room 236.

“This event comes on the heels of recently receiving the Drug Store News 2024 REX Technology and Automation Award,” states Host. “This is a huge step towards our vision of bringing these solutions together into one, and what better place to highlight this than where pharmacy started, New Orleans.”

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post Outcomes® Showcased at McKesson ideaShare 2024 first appeared on AI-Tech Park.

Empatica, a pioneer in digital biomarker development and patient monitoring driven by AI, today announced a partnership with Mobilise-D, an initiative funded by the Innovative Medicines Initiative (IMI) and EFPIA partners, and coordinated by Newcastle University. This collaboration will integrate Mobilise-D’s validated Digital Mobility Outcomes (DMOs) into Empatica’s Health Monitoring Platform, bringing it one step closer to becoming a single, unified destination for implementing digital endpoints in clinical care and research.

“We are proud to be the first non-consortium member to implement the Mobilise-D consortium’s groundbreaking development and validation work,” said Simone Tognetti, Empatica’s CTO and Co-founder. “This means our Platform can now provide 25 new, validated outcomes for COPD, Parkinson’s, Multiple Sclerosis, and Proximal femoral fracture. The demand for high-quality, purpose-specific measures is immense, and Empatica is ready to support the dissemination of the consortium’s innovative work within the industry.”

The project was launched to innovate ways to better assess people’s mobility in daily life using digital measures and wearable sensors, aiding therapeutic development, clinical practice, and precision medicine. With this partnership, all Mobilise-D DMOs can be measured with Empatica’s EmbracePlus wearable and accessed through the Empatica Health Monitoring Platform, consolidating advanced mobility analytics with Empatica’s robust technology.

Lynn Rochester, Professor at Newcastle University and Mobilise-D co-lead, said, “A major barrier to the implementation of digital outcomes in clinical trials is the availability of systems that can deliver accurate and reliable data in a timely and seamless manner. We are delighted that Empatica have chosen to integrate the Mobilise-D advanced mobility analytics, addressing this barrier and moving digital outcome assessment closer to a sustainable solution that drives much-needed innovation and harmonization in clinical trials.”

Providing Mobilise-D’s algorithms alongside Empatica’s service and technology makes it easier for pharma companies to include them in their studies, reducing patient and site burden. Mobilise-D is the first public program to systematically combine device considerations, analytical and clinical validation, and patient and regulatory engagement to generate reliable evidence for digital measures. The critical support from key pharmaceutical companies in the pipeline development leading to the dissemination of these endpoints highlights the collaborative effort required to drive innovation in the industry. Utilizing the algorithms in interventional clinical trial settings is a key step toward the regulatory approval of digital endpoints in clinical drug development.

Visit Empatica’s website to learn more about its full digital measure offering and how the Empatica Health Monitoring Platform can facilitate clinical care and research.

Empatica

Empatica Inc is a pioneer in continuous, unobtrusive remote health monitoring driven by AI. Empatica’s FDA-cleared platform and technology are used by thousands of institutional partners for research purposes, in studies examining stress, sleep, epilepsy, migraine, depression, addiction, and other conditions. Its flagship medical wearable, EmbracePlus, has been developed with key partners including HHS, USAMRDC, and the NASA-funded TRISH.

Mobilise-D

Mobilise-D is a consortium funded under the EU Innovative Medicines Initiative and EFPIA partners comprised of experts from 22 academic institutions, 12 industry partners from pharmaceutical, technology, and clinical research organisations, and people with diverse health conditions and mobility impairments. The primary objective of Mobilise-D was to develop a novel method to accurately and reliability assess change in one’s mobility in the real-world environment using digital technologies, including a single body-worn device. The project focused on conditions which affect mobility, including COPD, Parkinson’s disease, multiple sclerosis, hip fracture recovery, and congestive heart failure.

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post Empatica Announces Integration of Mobilise-D Mobility Outcomes first appeared on AI-Tech Park.

For nearly 25 years, Get Well has delivered digital, consumer-centric experiences to patients and their families throughout their care journeys. The Get Well 360 platform is personalized to individual healthcare needs, factoring in social determinants of health to help organizations provide world-class care. As part of the Get Well 360 platform, Get Well’s Smart Room offering provides patients with customizable options to take control over their experiences, expedite paperwork processes, and understand treatment plans. Leveraging AI-powered outreach solutions to reach patients at scale, the platform enables longitudinal engagement and activation to serve beyond the hospital setting on a long-term basis.

“When we founded Get Well, we were committed to creating a patient Smart Room that would transform the way patients experience their care and the way clinicians work. This recognition validates our commitment to empowering healthcare providers and helping them enhance patient satisfaction, improve outcomes, and drive long-term loyalty,” said Michael O’Neil, CEO and Founder of Get Well. “We’re proud to serve the majority of AVIA’s client base with our Smart Room technology and build upon our relationships with health system executives.”

The 2024 Top Smart Rooms Companies Report represents the aggregation and analysis of client ratings and reviews as well as health system implementation data across the country and highlights broader industry trends to contextualize the impact the companies and products are currently having in the space. Given the complexity and evolving nature of the Smart Rooms, the report helps define the Smart Rooms landscape and how these solutions best support patient access.

“Patients today expect a seamless, technology-enabled experience during their healthcare journey, and smart rooms are pivotal in meeting this demand. Our research underscores the transformative power of smart rooms in enhancing patient safety, comfort, and outcomes by integrating advanced monitoring, automation, and communication systems,” said Dhiraj Patkar, SVP of Digital Health Solutions at AVIA.

This announcement builds on recent recognition Get Well has received from market intelligence firms including being named to AVIA Marketplace’s list for Top Patient Education Companies and selected as the #1 Market Leader for Patient Driven Care by KLAS in their 2024 Best in KLAS report.

Access the full report findings from AVIA Marketplace’s Top Smart Rooms Companies list here.

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post Get Well Named to AVIA Marketplace’s 2024 Top Smart Rooms Companies first appeared on AI-Tech Park.

The MCP program, aimed at transforming primary care delivery and improving patient outcomes, presents unique challenges and requirements for participating providers. Compliance with program standards, including enhanced care coordination, patient engagement, and quality reporting, is paramount to driving success and achieving program objectives.

MCP Companion addresses these challenges by offering a comprehensive suite of features tailored to the needs of MCP providers:

• Care management tools including patient screening
• Claim data integration
• Patient stratification
• Preventable care cost risk drivers
• Next care steps
• Clinical summaries
• MCP-specific risk adjustment analytics
• Management and operational analytics and reports
• eConsult services
• The clinical and technology expertise to guide MCP participants at every stage

“We are excited to welcome a new cohort of physicians to value-based care and support them with MCP Companion, a solution that empowers them to deliver high-quality, coordinated care while navigating the complexities of the MCP program,” said Kira Radinsky, CEO of Diagnostic Robotics. “Our solutions have always focused on delivering the best cost and quality outcomes, and we’re delighted to support MCP participants with MCP Companion to help address their specific needs and program goals.”

MCP Companion is now available for MCP providers seeking to optimize their performance and achieve success in the MCP program. For more information or to request a demo, visit https://www.diagnosticrobotics.com/dr-mcp.

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post Diagnostic Robotics Introduces MCP Companion first appeared on AI-Tech Park.

 b.well Connected Health, the company powering platform-enabled healthcare ecosystems, today announced that it has been selected as winner of the “Patient Engagement Innovation Award” in the 8^th annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global digital health and medical technology market.

The b.well Connected Health platform is a Fast Healthcare Interoperability Resource (FHIR)-based solution that connects healthcare ecosystems – places where all health data, solutions and services are unified around consumers and their families. The company partners with healthcare organizations so they can build their own ecosystems and deliver unprecedented convenience via unified, on-demand consumer health experiences.

b.well’s solution enables healthcare organizations to freely exchange data with health systems, pharmacies, labs, payers, and patients who have consented to share their information. This is powered by b.well’s 60,000 live, consumer-mediated data connections, which include payer and provider application programming interfaces (APIs), health information networks (HINs), connected devices and wearables, labs, pharmacies, and more. By leveraging this data, b.well unlocks personalization and business value by alleviating administrative burden, reducing fragmentation, and improving quality measures and risk adjustment.

With a white-labeled application and integration into existing investments, b.well helps healthcare organizations  differentiate in the market while providing their consumers with longitudinal health records; receive proactive, personalized health insights; and conveniently shop and access care for themselves and their families. For example, b.well recently partnered with Samsung Health to give millions of people control over their health data, access to next-best actions to manage their health, and a direct connection to relevant in-person, digital, and virtual providers — all through an app on Galaxy smartphones.

As a result, organizations like Samsung and those within its ecosystem will be better able to respond to competitive, regulatory, and financial pressures; connect with consumers in new ways; and offer the connected healthcare experiences consumers and their families deserve.

“We’re on a mission to solve healthcare’s fragmentation problem, and we’re committed to empowering individuals and enhancing the overall healthcare experience by prioritizing the importance of interoperability in patient care,” said Kristen Valdes, CEO and Founder of b.well Connected Health. “The ‘Patient Engagement Innovation Award’ from MedTech Breakthrough is an honor that validates our determination to create a solution to power seamless personal, and accessible, modernized consumer healthcare experiences that can compete in the connected healthcare ecosystems of tomorrow.”

The mission of the MedTech Breakthrough Awards is to honor excellence and recognize the innovation, hard work and success in a range of health and medical technology categories, including Telehealth, Clinical Administration, Patient Engagement, Electronic Health Records (EHR), Virtual Care, Medical Devices, Medical Data & Privacy, and many more. This year’s program attracted thousands of nominations from over 18 different countries.

“b.well is helping consumers who are in need of navigation and personalization through our complex and fragmented healthcare system,” said Steve Johansson, managing director, MedTech Breakthrough. “Along with labor shortages and razor-thin margins, healthcare organizations face pressures from every angle without the right tech to facilitate consumer empowerment. b.well delivers on this need, providing a breath of fresh air in an industry stale with point solutions and siloed platforms. By providing the dynamic connectivity necessary to navigate the challenges of the healthcare system, b.well is delivering positive experiences for consumers and improved health outcomes.”

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post b.well Connected Health Receives “Patient Engagement Innovation Award” first appeared on AI-Tech Park.

Xealth, the leader in enabling digital health at scale, today announced that Stel Life, a leader in health monitoring device connectivity, has connected with Xealth’s digital health platform to bring vitals data from a patient’s device into the care team’s workflow faster and with added privacy, maintaining a no-protected health information (PHI) integration between Xealth and Stel.

Enrolling the patients is the first step in any remote patient monitoring (RPM) program, but the data needs to be easily accessible by researchers and care teams. Xealth’s integration into the EHR brings the Stel program into clinical workflows, ensuring that providers have instant access to important health data. Additionally, as an extra privacy measure, Stel’s integration with Xealth is implemented without health systems sharing PHI with Stel.

“We’re privileged to support innovative health systems in evolving care to the home and improving the overall health of the communities they serve,” said Sid Kandan, CEO of Stel Life. “We are excited to deploy Stel through the Xealth digital health platform, as not only does Xealth help power provider workflows, but also maintains our unidentified data design. We don’t need to know exactly who the patient is, but trust Xealth to get data to records.”

Stel Life seamlessly and securely connects wireless health devices to care teams using cellular networks that function even in areas with low broadband access. Stel Life’s ecosystem allows health systems to standardize their device connectivity across hundreds of devices, including scales, blood pressure cuffs, glucometers, continuous glucose monitors (CGMs), wearables, and more. This device data surfaces patient trends via Xealth’s digital health platform, enhances a hospital’s ability to monitor patients outside of the hospital, enabling tailored care plans, quicker interventions and better outcomes.

“We simplify digital access by improving access to care, both for patients and the providers responsible for their care,” said Mike McSherry, CEO of Xealth. “The Stel Hub works without patients needing smartphones or Wi-Fi, connecting care to track behavior and outcomes. We are excited to partner with Stel to make monitoring simpler and more secure.”

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post Xealth and Stel Life announced partnership first appeared on AI-Tech Park.

Pleio, Inc. and FountainRx announce their partnership to provide a concierge-level experience to specialty pharmacy patients. The two companies are launching a program to provide patients with human-driven support as they onboard onto their specialty medication to reduce stress.

FountainRx, a quintuple-accredited provider of specialty pharmacy, infusion, and compounding services, is committed to providing patients with better health and fewer hassles. “FountainRx understands the challenges that can come for patients when starting a specialty medication. As such, we are always seeking ways to provide our patients with a superior experience,” says Michele Kensik, VP of Pharma Relations at FountainRx. “Partnering with Pleio allows us to keep the personal attention on our patients, deliver more compassionate support, and better educate them through their journey.”

Pleio, a leading human-focused patient engagement provider, is extending novel concierge-level support through their proven GoodStart system. The partnership with FountainRx reinforces the commitment to supporting the emotional needs of patients onboarding onto new medications which ultimately builds trust and confidence with the patient. 

“Pleio appreciates FountainRx’s patient-centric culture and innovative approach to expanding the patient experience,” says Jennifer Butler, Chief Commercial Officer at Pleio. “The partnership recognizes that human touch is critical to reduce stress for patients and support their next step.”

Pleio’s program is embedded into FountainRx’s outreach process, creating a seamless experience for the patient and delivering efficiencies to FountainRx’s clinical team which ultimately provides clinical support to patients. The GoodStart system complements FountainRx’s clinical care team by supporting patients with a non-clinical discussion and helps to ease overwhelming feelings the patient may be experiencing.

In addition, the partnership program extends support to re-engage patients who have faced treatment interruptions and keeps them on the treatment path recommended by their provider. Pleio and FountainRx are collecting data to measure patient engagement, satisfaction, adherence lift, and operating efficiencies.

Connect with both Pleio and FountainRx at Asembia AXS24 in Las Vegas to learn more about this program.

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post Pleio, Inc. and FountainRx announce partnership first appeared on AI-Tech Park.

Gentry Health Services and Pleio, Inc. announce their partnership aimed at redefining the landscape of patient experience in specialty pharmacy. The two companies have launched a program to provide peer-to-patient support as patients initiate specialty medication therapy. 

Gentry Health Services, with its commitment to improving clinical outcomes for patients with the most complex disease states, has one primary focus: taking care of the patient. “We recognize the difficulties for patients in navigating the process of starting a specialty medication, especially for the first time.  Incorporating emotional awareness into understanding the patient’s needs lowers the barriers to successfully initiating therapy for the patient,” remarked Nimesh Patel, Chief Operating Officer at Gentry Health Services. “Our partnership with Pleio provides a wraparound patient support program to complement Gentry Health Services’ clinical care team.”

In early 2023, the American Medical Association identified that five out of the top eight reasons leading to non-adherence are due to emotional barriers.¹ Helping patients navigate the first 100-days of therapy with a human touch to overcome these emotional barriers is critical to enhancing clinical outcomes and elevating the patient experience.

Pleio offers patients a human-first connection, extending its GoodStart Program in partnership with Gentry Health Services to address patients’ emotional needs as they onboard onto treatment, building trust and confidence as they begin their healthcare journey. Pleio’s GoodStart program bridges a gap that exists in patient engagement by introducing pharma-sponsored resources for patients as they interact with specialty pharmacies.

“Pleio is seamlessly embedded into Gentry’s process to ensure every patient receives personalized, compassionate care,” said Mark Gregory, Chief Pharmacy Officer at Pleio. “We’ve worked together to design an elevated experience, so each patient feels motivated, appreciated, and heard.”

The partnership creates continued connectivity with patients, reduces interruptions in therapy, and complements Gentry Health Services’ clinical care team, which extends support to patients by providing information and education to ease overwhelming feelings. As Gentry Health Services and Pleio engage with patients, they collect data to measure patient engagement, satisfaction, adherence lift, and operating efficiencies. 

Connect with both Gentry Health and Pleio at Asembia AXS24 in Las Vegas to learn more about this program.

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post Gentry Health Services and Pleio, Inc. announce partnership first appeared on AI-Tech Park.

CipherHealth, a leader in patient engagement technology and communications solutions, today announced the availability of a Medication Affordability & Adherence Program to increase access to life-saving medications and improve adherence for patients. With this latest program, CipherHealth continues to pave the way in digital healthcare by including access to medication affordability options as a seamless part of outreach to patients.

When patients fail to adhere to medication plans due to costs—not filling prescriptions, delaying fills, or skipping or reducing doses—there are serious downstream consequences for individuals and population health. In fact, 67 percent of patients cite costs as the reason for not filling prescriptions and nonadherence to prescribed treatment is thought to cause at least 100,000 preventable deaths and $100 billion in preventable medical costs per year.

Underscoring the importance of medication affordability to the nation’s largest and most innovative healthcare organizations, CipherHealth is undertaking the initiative in partnership with leading health systems including Community Health Network and Prisma Health. Their leadership in providing much-needed support for patients highlights the need for additional patient-centered initiatives that can fundamentally change lives.  

“Addressing medication affordability is crucial to driving down the cost of healthcare and improving outcomes,” said Dr. Jonathan Gleason, Executive Vice President, Chief Clinical Officer at Prisma Health. “CipherHealth’s program provides an innovative solution to a major barrier that prevents many patients from adhering to their prescribed treatment plans.”

Nonadherence due to prescription drug costs also leads to higher mortality rates for patients with chronic illnesses. All of this underlines how critical it is to find ways to make medications more accessible for patients so they can recover, stay healthy and avoid rehospitalization.

“We are committed to exploring new ways to enhance the patient experience and make quality care more accessible,” said Dr. Patrick McGill, Executive Vice President, Chief Transformation Officer at Community Health Network. “Initiatives like this have great potential to positively impact both medication adherence and overall population health.”

CipherHealth’s Medication Affordability & Adherence Program can be offered to patients following a healthcare event, sent via CipherOutreach. Patients are connected via SMS with the best savings programs personalized for them based on their prescribed medications, insurance and pharmacy of choice. These benefits can then be applied to a patient’s medication by showing the pharmacist the instructions provided to the patient via CipherHealth’s outreach. The program can be used at over 70,000 pharmacies across the country.

“Prescription drug prices in the US are higher than in any other industrialized nation in the world. Many patients, despite having health insurance, are still unable to afford their medications,” said CipherHealth Chief Executive Officer Jake Pyles. “With this new program, CipherHealth is able to help reduce these medical costs and give patients the medication they need at a price they can afford.”

To learn more on how CipherHealth’s Medication Affordability and Adherence Program can help support and scale medication access for all patients, click here.

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post CipherHealth’s Medication Affordability & Adherence Program available first appeared on AI-Tech Park.